(VIANEWS) – Shares of BERGENBIO (Oslo Børs Benchmark Index_GI: BGBIO.OL) rose by a staggering 19.1% to kr0.35 at 11:23 EST on Thursday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is rising 0.22% to kr1,230.30, following the last session’s upward trend. This seems, as yet, a somewhat up trend trading session today.
About BERGENBIO
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Earnings Per Share
As for profitability, BERGENBIO has a trailing twelve months EPS of kr-2.85.
Volatility
BERGENBIO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 6.74%, a negative 5.15%, and a positive 8.68%.
BERGENBIO’s highest amplitude of average volatility was 9.40% (last week), 20.71% (last month), and 8.68% (last quarter).
More news about BERGENBIO (BGBIO.OL).
